Future Oncology
Overview
Future Oncology is a peer-reviewed journal dedicated to advancing the understanding and treatment of cancer. It provides a platform for cutting-edge research, clinical trials, and expert opinions on emerging therapies, diagnostics, and personalized medicine. With a focus on the future of oncology, this journal aims to improve patient outcomes and shape the direction of cancer care worldwide.
Details
Details
Abbr.
Future Oncol
Start
2005
End
Continuing
Frequency
Forty no. a year, 2022-
p-ISSN
1479-6694
e-ISSN
1744-8301
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 3682
90
SJR / Ranks: 3629
1029
CiteScore / Ranks: 4778
5.20
JIF / Ranks: 3040
3.3
Recent Articles
11.
Marhold M, Vaz Batista M, Blancas I, Morales C, Saura-Manich C, Saavedra C, et al.
Future Oncol
. 2025 Feb;
:1-9.
PMID: 40018758
NCT06048718 (clinicaltrials.gov); 2023 -506,702-39-00 (EudraCT number).
12.
Hamilton E, Loibl S, Bachelot T, Gnant M, Niikura N, Park Y, et al.
Future Oncol
. 2025 Feb;
21(7):795-806.
PMID: 40017004
Novel selective estrogen receptor degraders (SERDs) are a promising therapeutic option under investigation for patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The efficacy of...
13.
Ailawadhi S, Inocencio T, Mansfield C, Chintakayala P, Bussberg C, Chi L, et al.
Future Oncol
. 2025 Feb;
21(7):853-865.
PMID: 40012263
Aims: To quantify patient preferences for attributes of novel treatments for triple-class-exposed (TCE) relapsed and/or refractory multiple myeloma (RRMM). Methods: Using a discrete-choice experiment, we elicited preferences for 7 attributes:...
14.
Zhang Y, Wu M, Jin Z, Yang L, Huang X, Li W, et al.
Future Oncol
. 2025 Feb;
:1-6.
PMID: 40008672
Acute myeloid leukemia (AML) treatment relied on anthracyclines and cytarabine based intensive chemotherapy. However, clinical outcomes are unsatisfied for patients with intermediate/adverse cytogenetics based on European Leukemia Net (ELN) risk...
15.
Pal S, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman D, Barata P, et al.
Future Oncol
. 2025 Feb;
21(7):787-794.
PMID: 40008409
Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with immune checkpoint inhibitor (ICI)...
16.
17.
Johnsen S, Baas P, Sorensen J, Chouaid C, Griesinger F, Daumont M, et al.
Future Oncol
. 2025 Feb;
21(7):867-878.
PMID: 39996596
In recent years, the thoracic malignancies treatment landscape has become more complex with the emergence of novel targeted and immunotherapy-based treatments. Although beneficial to patients and physicians, this fast-paced therapeutic...
18.
Hepatic steatosis development as a long-term complication among testicular germ cell tumor survivors
Akkus E, Karaosmanoglu A, Gulpinar B, Suer E, Urun Y
Future Oncol
. 2025 Feb;
:1-8.
PMID: 39995254
Background: Hepatic steatosis (HS) development and its risk factors in testicular germ cell tumor (TGCT) survivors have not been investigated. Methods: The study was designed as a retrospective observational study....
19.
Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S, et al.
Future Oncol
. 2025 Feb;
:1-13.
PMID: 39995095
No abstract available.
20.
Leger P, Frencher Jr S, Nauseef J, Jones B, Bilen M, Brown Jr A, et al.
Future Oncol
. 2025 Feb;
:1-7.
PMID: 39992723
Aims: This study aimed to partner with patients, advocates, and physicians to better understand the barriers that exist for Black and African Americans to enroll in prostate cancer (PCa) clinical...